Advertisement

News Stories

Mar, 2018

ORLANDO (March 10, 2018) – The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally tolerated statin and placebo. 

0
No votes yet
Name: Top Stories
Jan, 2018

JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program. The partnership will also include sister publications, Rare Disease Report® and Pharmacy Times®.

0
No votes yet
Name: Top Stories
Dec, 2017


Nominations are now open for the National Lipid Association Board of Directors and Chapter officers and will be accepted until 5 p.m. EST on February 2, 2018.

To submit a nomination and for more information on the process, visit lipid.org/nominate.

0
No votes yet
Name: NLA News

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service